Abstract

The present disclosure describes variant tryptophan synthases (TrpS) and their use in recombinant host cells to produce L-cysteine and/or L-cystine.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 9/88 - Lyases (4.)
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present disclosure describes genetically modified host cells expressing or overexpressing one or more genes of an L-serine pathway, or an operon comprising such one or more genes, wherein the genes or operon are operably linked to a constitutive promoter having a nucleotide sequence which is at least 70 %, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, such as at least 99%, such as 100% identical to the constitutive promoter comprised in anyone of SEQ ID NO: 1 to 16.

IPC Classes  ?

• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/10 - Transferases (2.)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 13/06 - AlanineLeucineIsoleucineSerineHomoserine

Abstract

The present invention generally relates to the use of hydroxycinnamic acid or derivatives thereof, such as zosteric acid in a cosmetic or therapeutic setting. The present invention further relates to compositions comprising hydroxycinnamic acid or derivatives thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/06 - Antipsoriatics
• A61P 17/08 - Antiseborrheics
• A61P 17/10 - Anti-acne agents
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations
• A61Q 5/00 - Preparations for care of the hair
• A61K 8/368 - Carboxylic acidsSalts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings

Abstract

The present invention relates to a low dose formulation of L-serine for liver health and fatty liver diseases. More particularly, the present invention provides a formulation of L-serine for which the daily dose is between 2 and 15 g per person per day. The claimed formulations are efficacious and useful for fatty liver disease patients and individuals at risk of developing a fatty liver disease including individuals with elevated liver fat levels. Furthermore, the present invention provides novel efficient methods of use of such formulations.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a genetically engineered host cell producing a metabolite from 3- phosphoglycerate through a metabolic pathway, comprising one or more genetic modifications preventing or reducing or alleviating a negative impact on production of the metabolite from intracellular accumulation of NADH and/or hydroxy glutarate (HGA), produced by one or more pathway enzymes.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• C12P 13/06 - AlanineLeucineIsoleucineSerineHomoserine

Abstract

The present invention generally relates to the agricultural industry, and specifically to the protection of crops, seeds and fruits against fungal and/or oomycetes pests. The present invention provides the use of hydroxycinnamic acid or a derivative thereof for protection of crops, seeds or fruits against at least one fungal and/or oomycetes pest, wherein a composition comprising hydroxycinnamic acid or a derivative thereof is applied to the surface of said crops, seeds or fruits by spraying or by immersion into said composition.

IPC Classes  ?

• A01N 31/16 - Oxygen or sulfur directly attached to an aromatic ring system with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
• A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
• A01P 3/00 - Fungicides

Goods & Services

Fermentation extract; Fermentation extracts for industrial purposes; Sulfates; Flavonoids [phenolic compounds] for industrial purposes; Phenolic resins; Bacterial substances for scientific use; Bacterial substances for industrial use; Biochemical precursors for scientific purposes; Chemical polymers; Polymers for use in the analysis of biochemicals; Chemical and organic compositions for use in the manufacture of food and beverages; Chemical substances, chemical materials and chemical preparations, and natural elements; Acids; Organic acids for industrial use; Aromatics [chemicals]. Pharmaceuticals and natural remedies; Medical and veterinary preparations and articles. Research and development in the field of microorganisms and cells; Biochemical engineering services; Research and development services; Biochemical research and development; Pharmaceutical research and development; Scientific research and development; Research and development in the field of biotechnology; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of bacteriology; Science and technology services; Natural science services; Medical and pharmacological research services; Engineering services.

Abstract

The present disclosure describes a method for producing cysteine and/or cystine comprising a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes capable of converting serine into cysteine and/or cystine in the presence of the source of sulfur; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of PLP and the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine.

IPC Classes  ?

• C12N 9/88 - Lyases (4.)
• C12P 13/12 - MethionineCysteineCystine

Goods & Services

Amino acids for industrial purposes; Amino acids for scientific purposes; Fermentation extract; Fermentation extracts for industrial purposes; Sulfates; Flavonoids for industrial purposes [phenolic compounds]; Phenolic resins; Bacterial substances for scientific use; Bacterial substances for industrial use; Biochemical precursors for scientific purposes; Chemical polymers; Polymers for use in the analysis of biochemicals; Chemical and organic compositions for use in the manufacture of food and beverages; Chemical substances, chemical materials and chemical preparations, and natural elements; Acids; Organic acids for industrial use; Aromatics [chemicals]; all the aforementioned being genetically engineered raw materials produced by a genetically engineered microbe; none of the aforementioned being for in vitro diagnostics or immunoassays. Amino acids for medical purposes; Amino acids for veterinary purposes; Amino acids for medical or veterinary purposes; Pharmaceuticals and natural remedies; Medical and veterinary preparations and articles; none of the aforementioned being finished preparations to be used for in vitro diagnostics or immunoassays; none of the aforementioned being for in vitro diagnostics or immunoassays. Research and development in the field of microorganisms and cells; Biochemical engineering services; Research and development services; Biochemical research and development; Pharmaceutical research and development; Scientific research and development; Research and development in the field of biotechnology; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of bacteriology; Science and technology services; Natural science services; Medical and pharmacological research services; Engineering services; none of the aforementioned being research on in vitro diagnostics and immunoassays.

Goods & Services

Amino acids for industrial purposes; Amino acids for scientific purposes; Fermentation extract; Fermentation extracts for industrial purposes; Sulfates; Flavonoids for industrial purposes [phenolic compounds]; Phenolic resins; Bacterial substances for scientific use; Bacterial substances for industrial use; Biochemical precursors for scientific purposes; Chemical polymers; Polymers for use in the analysis of biochemicals; Chemical and organic compositions for use in the manufacture of food and beverages; Chemical substances, chemical materials and chemical preparations, and natural elements; Acids; Organic acids for industrial use; Aromatics [chemicals]; all the aforementioned being genetically engineered raw materials produced by a genetically engineered microbe; none of the aforementioned being for in vitro diagnostics or immunoassays. Amino acids for medical purposes; Amino acids for veterinary purposes; Amino acids for medical or veterinary purposes; Pharmaceuticals and natural remedies; Medical and veterinary preparations and articles; none of the aforementioned being finished preparations to be used for in vitro diagnostics or immunoassays; none of the aforementioned being for in vitro diagnostics or immunoassays. Research and development in the field of microorganisms and cells; Biochemical engineering services; Research and development services; Biochemical research and development; Pharmaceutical research and development; Scientific research and development; Research and development in the field of biotechnology; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of bacteriology; Science and technology services; Natural science services; Medical and pharmacological research services; Engineering services; none of the aforementioned being research on in vitro diagnostics and immunoassays.

Abstract

The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using polypeptides or recombinant cells comprising said polypeptides. More particularly, the present invention pertains to polypeptides having aryl sulfotransferase activity, recombinant host cells expressing same and processes for the production of aryl sulfates employing these polypeptides or recombinant host cells.

IPC Classes  ?

• C12N 9/88 - Lyases (4.)
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/10 - Transferases (2.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/67 - General methods for enhancing the expression
• C12P 11/00 - Preparation of sulfur-containing organic compounds

Abstract

The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using recombinant host cells. More particularly, the present invention pertains to recombinant host cells comprising (e.g., expressing) a polypeptide having aryl sulfotransferase activity, wherein said recombinant host cells have been modified to have an increased uptake of sulfate compared to identical host cells that does not carry said modification. Further provided are processes for the production of aryl sulfates, such as zosteric acid, employing such recombinant host cells.

IPC Classes  ?

• C12P 11/00 - Preparation of sulfur-containing organic compounds
• C12N 9/10 - Transferases (2.)
• C12P 5/00 - Preparation of hydrocarbons

Abstract

The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

IPC Classes  ?

• C12N 1/36 - Adaptation or attenuation of cells
• C12N 1/20 - BacteriaCulture media therefor
• C12P 13/06 - AlanineLeucineIsoleucineSerineHomoserine
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/10 - Transferases (2.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 9/88 - Lyases (4.)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• C12N 9/90 - Isomerases (5.)
• C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings
• C12P 13/22 - TryptophanTyrosinePhenylalanine3,4-Dihydroxyphenylalanine
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12P 13/12 - MethionineCysteineCystine
• C07K 14/245 - Escherichia (G)
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)

Abstract

The present invention generally relates to the field of biotechnology as it applies to the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity. More particularly, the present invention pertains to polypeptides having tyrosine ammonia lyase activity and high substrate specificity towards tyrosine, which makes them particularly suitable in the production of p-coumaric acid and other hydroxycinnamic acids. The present invention thus provides processes for the production of p-coumaric acid and other hydroxycinnamic acids employing these polypeptides as well as recombinant host cells expressing same.

IPC Classes  ?

• C12P 7/42 - Hydroxy carboxylic acids
• C12N 9/88 - Lyases (4.)

Abstract

The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using polypeptides or recombinant cells comprising said polypeptides. More particularly, the present invention pertains to polypeptides having aryl sulfotransferase activity, recombinant host cells expressing same and processes for the production of aryl sulfates employing these polypeptides or recombinant host cells.

IPC Classes  ?

• C12P 11/00 - Preparation of sulfur-containing organic compounds
• C12N 9/10 - Transferases (2.)
• C12N 9/18 - Carboxylic ester hydrolases
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 9/88 - Lyases (4.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/67 - General methods for enhancing the expression

Abstract

The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using recombinant host cells. More particularly, the present invention pertains to recombinant host cells comprising (e.g., expressing) a polypeptide having aryl sulfotransferase activity, wherein said recombinant host cells have been modified to have an increased uptake of sulfate compared to identical host cells that does not carry said modification. Further provided are processes for the production of aryl sulfates, such as zosteric acid, employing such recombinant host cells.

IPC Classes  ?

• C12P 11/00 - Preparation of sulfur-containing organic compounds
• C12N 9/10 - Transferases (2.)
• C12P 5/00 - Preparation of hydrocarbons

Abstract

The present invention generally relates to the microbiological industry, and specifically to the production of L-serine using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• C12P 13/06 - AlanineLeucineIsoleucineSerineHomoserine
• C12P 13/12 - MethionineCysteineCystine
• C12P 13/22 - TryptophanTyrosinePhenylalanine3,4-Dihydroxyphenylalanine
• C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings
• C12N 1/36 - Adaptation or attenuation of cells
• C07K 14/245 - Escherichia (G)
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/10 - Transferases (2.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 9/88 - Lyases (4.)
• C12N 9/90 - Isomerases (5.)
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)

Abstract

The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• C12N 1/36 - Adaptation or attenuation of cells
• C12P 13/06 - AlanineLeucineIsoleucineSerineHomoserine
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/10 - Transferases (2.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 9/88 - Lyases (4.)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 9/90 - Isomerases (5.)
• C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings
• C12P 13/22 - TryptophanTyrosinePhenylalanine3,4-Dihydroxyphenylalanine
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12P 13/12 - MethionineCysteineCystine
• C07K 14/245 - Escherichia (G)
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)

Abstract

The present invention relates to the production of hydrolyzates from a lignocellulose-containing material, and to fermentation of the hydrolyzates. More specifically, the present invention relates to the detoxification of phenolic inhibitors and toxins formed during the processing of lignocellulose-containing material by enzymatically sulfating the phenolic inhibitors and toxins using aryl sulfotranseferases.

IPC Classes  ?

• C12P 7/14 - Multiple stages of fermentationMultiple types of microorganisms or reuse for microorganisms
• C12P 5/00 - Preparation of hydrocarbons
• C12N 9/10 - Transferases (2.)
• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

The present invention generally relates to the field of biotechnology as it applies to the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity. More particularly, the present invention pertains to polypeptides having tyrosine ammonia lyase activity and high substrate specificity towards tyrosine, which makes them particularly suitable in the production of p-coumaric acid and other hydroxycinnamic acids. The present invention thus provides processes for the production of p-coumaric acid and other hydroxycinnamic acids employing these polypeptides as well as recombinant host cells expressing same.

IPC Classes  ?

• C12P 7/42 - Hydroxy carboxylic acids
• C12N 9/88 - Lyases (4.)